$1.28 Earnings Per Share Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter

Brokerages forecast that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will report earnings per share of $1.28 for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings. The highest EPS estimate is $1.53 and the lowest is $1.11. Alexion Pharmaceuticals posted earnings per share of $1.26 during the same quarter last year, which suggests a positive year over year growth rate of 1.6%. The business is scheduled to issue its next quarterly earnings results on Thursday, February 15th.

According to Zacks, analysts expect that Alexion Pharmaceuticals will report full year earnings of $5.67 per share for the current year, with EPS estimates ranging from $5.50 to $5.90. For the next fiscal year, analysts forecast that the company will report earnings of $7.11 per share, with EPS estimates ranging from $6.49 to $8.64. Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.12. The firm had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.23 earnings per share.

A number of equities research analysts have issued reports on ALXN shares. Royal Bank of Canada increased their price objective on shares of Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Stifel Nicolaus reduced their price objective on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research note on Tuesday, October 24th. Leerink Swann reiterated a “buy” rating and set a $182.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. SunTrust Banks reiterated a “buy” rating and set a $180.00 price objective (up from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Finally, Deutsche Bank reiterated a “buy” rating and set a $158.00 price objective (up from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $155.70.

Shares of Alexion Pharmaceuticals (ALXN) traded down $0.67 during trading on Thursday, reaching $119.59. 1,069,653 shares of the company’s stock were exchanged, compared to its average volume of 1,989,982. The firm has a market capitalization of $26,717.60, a P/E ratio of 53.39, a price-to-earnings-growth ratio of 1.30 and a beta of 1.18. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34.

Several institutional investors and hedge funds have recently bought and sold shares of ALXN. Gamco Investors INC. ET AL bought a new position in Alexion Pharmaceuticals in the 2nd quarter valued at approximately $487,000. Prudential Financial Inc. raised its holdings in Alexion Pharmaceuticals by 24.9% in the 2nd quarter. Prudential Financial Inc. now owns 387,488 shares of the biopharmaceutical company’s stock valued at $47,146,000 after buying an additional 77,360 shares during the last quarter. Penserra Capital Management LLC raised its holdings in Alexion Pharmaceuticals by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 144 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in Alexion Pharmaceuticals by 820.6% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 9,850 shares of the biopharmaceutical company’s stock valued at $1,198,000 after buying an additional 8,780 shares during the last quarter. Finally, Andra AP fonden bought a new position in Alexion Pharmaceuticals in the 2nd quarter valued at approximately $973,000. Institutional investors own 94.26% of the company’s stock.

TRADEMARK VIOLATION WARNING: “$1.28 Earnings Per Share Expected for Alexion Pharmaceuticals, Inc. (ALXN) This Quarter” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/31/1-28-earnings-per-share-expected-for-alexion-pharmaceuticals-inc-alxn-this-quarter.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit